INVITED RESEARCH HIGHLIGHT
Year : 2014  |  Volume : 16  |  Issue : 3  |  Page : 407-412

Next generation patient-derived prostate cancer xenograft models


1 The Vancouver Prostate Centre, Vancouver General Hospital; Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, Canada
2 Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, Canada
3 The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, Canada
4 The Vancouver Prostate Centre, Vancouver General Hospital; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
5 The Vancouver Prostate Centre, Vancouver General Hospital; Department of Experimental Therapeutics, British Columbia Cancer Agency and Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence Address:
Yuzhuo Wang
The Vancouver Prostate Centre, Vancouver General Hospital; Department of Experimental Therapeutics, British Columbia Cancer Agency and Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia
Canada
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.125394

Rights and Permissions

There is a critical need for more effective therapeutic approaches for prostate cancer. Research in this area, however, has been seriously hampered by a lack of clinically relevant, experimental in vivomodels of the disease. This review particularly focuses on the development of prostate cancer xenograft models based on subrenal capsule grafting of patients' tumor tissue into nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. This technique allows successful development of transplantable, patient-derived cancer tissue xenograft lines not only from aggressive metastatic, but also from localized prostate cancer tissues. The xenografts have been found to retain key biological properties of the original malignancies, including histopathological and molecular characteristics, tumor heterogeneity, response to androgen ablation and metastatic ability. As such, they are highly clinically relevant and provide valuable tools for studies of prostate cancer progression at cellular and molecular levels, drug screening for personalized cancer therapy and preclinical drug efficacy testing; especially when a panel of models is used to cover a broader spectrum of the disease. These xenograft models could therefore be viewed as next-generation models of prostate cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3698    
    Printed52    
    Emailed0    
    PDF Downloaded539    
    Comments [Add]    
    Cited by others 13    

Recommend this journal